Ally Invest Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$231K Sell
6,852
-524
-7% -$15.7K 0.01% 75
2026
Q1
$214K Sell
7,376
-935
-11% -$27.1K 0.01% 75
2025
Q4
$218K Sell
8,311
-1,244
-13% -$32K 0.02% 75
2025
Q3
$226K Buy
+9,555
New +$211K 0.02% 75

Other funds holding IDNA

Ally Invest Advisors's IDNA Position: Q2 2026 in Review

Ally Invest Advisors reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 7.1% in Q2 2026, selling an estimated $15.7K and leaving 6,852 shares worth $231K. The position accounts for 0.01% of the portfolio, ranked #75.

Ally Invest Advisors first reported a position in IDNA in Q3 2025 and has held it in 4 quarters since. 65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

  • Ally Invest Advisors held 6,852 shares of iShares Genomics Immunology and Healthcare ETF worth $231K as of Q2 2026.
  • Ally Invest Advisors sold 524 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $15.7K.
  • iShares Genomics Immunology and Healthcare ETF made up 0.01% of Ally Invest Advisors's portfolio in Q2 2026, its #75 holding.
  • Ally Invest Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2025 and has held it in 4 quarters since.
  • 65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Ally Invest Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.